Cutaneous toxicities in melanoma patients receiving checkpoint inhibitor therapy, a retrospective review: The experience of a single large specialist institution.

Please login or register to bookmark this article
Bookmark this %label%

CPI was approved by the European Medicines Agency (EMA) in 2012 for advanced melanoma and extended to include adjuvant melanoma treatment in 2018. Expectation for survival in advanced melanoma now exceeds 50% at 5 years with first-line combination ipilimumab and nivolumab. Cutaneous irAEs occur in up to 50% receiving ipilimumab and 40% receiving anti-programmed cell death 1 inhibitors. The majority of cutaneous toxicities are mild, however severe reactions are reported.

Get PDF with LibKey
View the article @ Clinical and experimental dermatology (sign-in may be required)